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Introduction 
Measurement of short term lower leg growth with 
the knemometer has recently been shown to be a 
sensitive method for assessment of systemic activity 
of exogeneous glucocorticosteroids in children with 
asthma (1). It is not known, however, whether short 
term knemometry is more sensitive than established 
measures of adrenal function, such as 24 h urine free 
cortisol excretion. We recently found that knemomet- 
ric growth rates were suppressed in a dose-related 
manner in asthmatic children treated with 200, 400 
and 800,~g of inhaled budesonide (2). In the present 
paper, we report the 24 h urine free cortisol excretion 
in the same children for comparison with the 
knemometry data, to evaluate if there is any correla- 
tion between the two measures of systemic activity, 
and to assess which method is the more sensitive. 
Patients and Methods 
The protocol was part of a clinical study of the 
influence of inhaled budesonide on short term lower 
leg growth assessed with the knemometer (2). Nine 
boys and six girls aged 6-13 (mean 9.5) years with 
mild asthma participated in the study. The children 
were pre-adolescent outpatients in a secondary 
referral centre. 
The study was approved by the local Ethical 
Committee and informed consent was obtained from 
all children and their parents. 
The design was a randomized double-blind, cross- 
over trial with four periods of 18 days. In periods 1 
(run-in) and 3 (wash-out), placebo was given, and in 
periods 2 and 4, the children took 200 or 8OOpg 
budesonide day - ‘. Treatment order was allocated 
by means of a computerized randomization scheme 
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prepared in balanced blocks. The scheduled double- 
blind study was prolonged with a placebo period 
(period 5) and an open 400,ug budesonide period 
(period 6). Budesonide was taken at 7.30 a.m. and 
7.30 p.m. as two puffs from a conventional pressur- 
ized metered dose inhaler with a large volume spacer 
(Nebuhaler”“). 
The children were instructed to collect urine during 
the last Saturday of the first period (run-in) and of 
the three budesonide treatment periods. Aliquots for 
determination of creatinine and cortisol were col- 
lected from the 24 -h urine samples, after weighing 
and thorough mixing of the whole volume. The 
aliquots were frozen until the end of the trial when 
urine free cortisol concentrations were measured by 
radioimmunoassay (Farmos Diagnostica, Turku, 
Finland) (3). The intra- and interassay coefficients of 
variation were 1.4% and 7.1%, respectively. The 
cortisol concentrations were standardized in ,ug g ~ ’ 
creatinine (4). 
ANALYSIS 
The creatinine standardized cortisol data were 
compared by the method described for cross-over 
trial designs (5). Neither period nor carry-over effects 
were found. Page’s test was used to evaluate if 
there was any dose-related influence of budesonide 
on urine cortisol excretion (6). Correlation be- 
tween lower leg growth velocities and urine cortisol 
concentrations during the run-in period and during 
each dose level of budesonide was assessed by 
Spearman’s test. The 5% level was considered as 
significant. 
Results 
Figure 1 shows individual and group mean urine 
free cortisol/creatinine x lo6 and the previously pub- 
lished knemometry data during the run-in period and 
at each dosage level of inhaled budesonide. No 
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Fig. I Twenty-four hours urine free cortisol excretion 
(UFC) and lower leg growth rates in 14 children during 
run-in, double-blind treatment with 2OOpg and 8OOpg 
budesonide, and in 12 children during open treatment with 
400 pg budesonide day - ’ 
statistically significant dose-related influence of 
budesonide treatment was found on urine free corti- 
sol levels either when the open 400,~g period was 
excluded from analysis (P=O.13; z= - 1.5) or when 
it was included (P=O.O6; z= - 1.8). The mean reduc- 
tion (SEM) during treatment with 200,400 and 800 pug 
budesonide was 2.2 (1.4), 2.1 (1.0) and 2.6 (1.5) 
cortisol/creatinine X lo6 respectively. 
Figure 2 compares individual delta values (run-in 
treatment) of lower leg growth rates and urine free 
cortisol/creatinine x 106. The correlation coefficient 
was - 0.18; t= - 1.18; P=O.12. Correlation analyses 
were also performed within each dose group, showing 
no statistically significant results. 
Discussion 
The present study seems to be the first dose- 
response study in children that has included a 
steroid-free run-in period for comparison of the urine 
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Fig. 2 Relation between treatment-induced changes in 
lower leg growth rate and 24 h urine free cortisol excretion 
(UFC) in 14 children during double-blind treatment with 
2OOpg and 8OOpg budesonide, and in 12 children during 
open treatment with 4OOpg budesonide day- ‘. No corre- 
lation was seen (r= - 0.18; t= - 1.18; P=O.12). 
cortisol levels during treatment periods. No signifi- 
cant dose-related effects of budesonide could be 
detected from the urine cortisol levels. This is in 
agreement with the findings of another cross-over 
study of a larger, but otherwise comparable, popu- 
lation which evaluated inhaled budesonide in similar 
doses (7). 
It is possible that nocturnal integrated plasma 
cortisol levels may be more sensitive in detecting 
effects on the hypothalamic-pituitary-adrenal feed- 
back system than extended period measurements of 
urine free cortisol excretion. We wanted, however, to 
evaluate if we could use a simpler method than 
knemometry to assess systemic activity. Further- 
more, results from studies using both integrated 
plasma levels of cortisol and urine free cortisol excre- 
tion measurements have been similar (8). 
Though it is possible that a few more patients in 
the study group would have resulted in a statistically 
significant correlation between the changes in growth 
rates and cortisol excretion, the present data show 
quite clearly that measurement of 24-h urine free 
cortisol excretion is not as sensitive as short term 
knemometry in detecting systemic effects of exo- 
geneous glucocorticosteroids in children. When 
new inhaled glucocorticosteroids, administration 
forms, regimens and inhalation devices are 
introduced in the management of children with 
asthma, knemometry should be preferred to 24-h 
urine free cortisol excretion for assessment of the 
lowest dose at which systemic activity can be 
detected. 
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